期刊
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
卷 28, 期 2, 页码 310-325出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1078155221989404
关键词
Breast cancer; tamoxifen resistance; PAX2; AIB1; promoter methylation
资金
- Mashhad University of Medical Sciences, Mashhad, Iran [921853]
This study found that aberrant promoter methylation of PAX2 and overexpression of AIB1 are associated with tamoxifen response in breast carcinoma patients, which may serve as predictive or prognostic biomarkers. Further research is needed to explore the potential of using PAX2 and AIB1 expression and their methylation-mediated regulation as a new target therapy for better disease management.
Introduction Disease recurrence is an important obstacle in estrogen receptor positive (ER+) tamoxifen treated breast carcinoma patients. Tamoxifen resistance-related molecular mechanisms are not fully understood. Alteration in DNA methylation which contributes to transcriptional regulation of cancer-related genes plays a crucial role in tamoxifen response. In the present study, the contribution of promoter methylation and mRNA expression of PAX2 and AIB1 in the development of breast carcinoma and tamoxifen refractory was assessed. Methods Methylation specific-high resolution melting (MS-HRM) analysis and Real-time quantitative PCR (RT-qPCR) experiment were performed to analyze the promoter methylation and mRNA expression levels of PAX2 and AIB1 genes in 102 breast tumors and adjacent normal breast specimens. Results We indicated that PAX2 expression is decreased in breast tissues due to hypermethylation in its promoter region. Compared to the adjacent normal tissues, the tumors exhibited significantly lower relative mRNA levels of PAX2 and increased expression of AIB1. Aberrant promoter methylation of PAX2 and overexpression of AIB1 was observed in tamoxifen resistance patients compared to the sensitive ones. Cox regression analysis exhibited that the increased promoter methylation status of PAX2 and overexpression of AIB1 remained as unfavorable identifiers which influence patients' survival independently. Conclusions Our results revealed that the aberration in PAX2 promoter methylation and AIB1 overexpression are associated with the tamoxifen response in breast carcinoma patients. Further research is needed to demonstrate the potential of using PAX2 and AIB1 expression and their methylation-mediated regulation as predictive or prognostic biomarkers or as a new target therapy for better disease management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据